Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.